Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (7.607.337 €): Anwendung von omics-basierten Strategien zur verbesserten Diagnose und Behandlung von endokriner Hypertonie Hor01.05.2015 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Anwendung von omics-basierten Strategien zur verbesserten Diagnose und Behandlung von endokriner Hypertonie
Arterial hypertension affects up to 45% of the general population and is responsible for 7.1 million deaths per year worldwide. Although a large therapeutic arsenal exists, blood pressure control is sub-optimal in up to two thirds of patients. Yet, even small increments in blood pressure are associated with increased cardiovascular risk, with 62% of cerebrovascular disease and 49% of ischemic heart disease being attributable to hypertension. Detection of secondary forms of hypertension is key to targeted management of the underlying disease and prevention of cardiovascular complications. Endocrine forms of hypertension represent major targets for stratified approaches of health promotion. They include a group of adrenal disorders resulting in increased production of hormones affecting blood pressure regulation: primary aldosteronism (PA), pheochromocytoma/functional paraganglioma (PPGL) and Cushing’s syndrome (CS). These diseases are associated with increased cardiovascular and metabolic risk and with diminished quality of life. This project will develop and evaluate an omics-based stratified health promotion program for patients with endocrine forms of hypertension. We will define specific omics profiles for patients with PA, PPGL and CS by integrating high throughput genetics, genomics and metabolomics data with phenome annotations through bioinformatics modelling. Established profiles will be validated as stratification biomarkers and applied to the screening of referred hypertensive patients for both stratifying primary forms of hypertension for effective and cost efficient therapy as well as improving identification of endocrine causes for curative treatment and prevention of cardiovascular and metabolic complications. Omics-based profiling should allow identification of patients with preclinical phenotypes along with those hypertensives that cluster into specific endocrine groups who may benefit from personalised treatment.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Assistance Publique Hopitaux de Paris | 988.500 € |
| 0,00 € | |
| HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM für GESUNDHEIT UND UMWELT GmbH | 534.048 € |
| Inserm Transfert SA | 408.374 € |
| Institut National de la Sante et de la Recherche Medicale | 1.443.501 € |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 17.871,64 € |
| Stichting Radboud Universitair Medisch Centrum | 157.714 € |
| 502.939 € | |
| TECHNISCHE UNIVERSITAET DRESDEN | 446.459 € |
| 0,00 € | |
| The University of Birmingham | 309.326 € |
| Universita Degli Studi DI Padova | 734.500 € |
| Universita Degli Studi DI Torino | 285.969 € |
| University OF Melbourne | 0,00 € |
| University of Dundee | 1.011.755 € |
| University of Glasgow | 766.380 € |
Quelle: https://cordis.europa.eu/project/id/633983
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Assistance Publique Hopitaux de Paris - EU-Förderung (7.607.337 €): Anwendung von omics-basierten Strategien zur verbesserten Diagnose und Behandlung von endokriner Hypertonie"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
